Incyte INCY Axatilimab - Development Activities — Accrued and other liabilities

Similar metrics at other companies

SANABothell Washington — Accrued Liabilities And Other Liabilities

$400K0.0%

HCIConsolidated Variable Interest Entities — Accrued Liabilities And Other Liabilities

$3.81M—

RARECommercial And Development Activity Reimbursements — Accrued Liabilities Current And Noncurrent

$16M+61.6%

KBHHomebuilding — Accrued Liabilities

$704.4M-8.7%

NVRHome Building Segment — Accrued expenses and other liabilities

$311.7M-6.5%

KBHHomebuilding — Accounts payable and other liabilities

$18.23M+75.1%

FAQ

What is Incyte's axatilimab - development activities — accrued and other liabilities?

Incyte (INCY) reported axatilimab - development activities — accrued and other liabilities of $1.4M in Q2 2026.

What does axatilimab - development activities — accrued and other liabilities mean?

This metric represents the outstanding financial obligations and liabilities specifically attributed to the research and development activities of the Axatilimab program. It captures accrued expenses for clinical trials, manufacturing development, and regulatory filing costs that have been incurred but not yet settled in cash. Monitoring this balance provides insight into the near-term cash outflow requirements and the intensity of development efforts for this specific therapeutic asset.